Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating ...

SAN DIEGO -- Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly migraine ...

Migraine is a complex neurological disease that affects about 1 billion people globally. It is associated with a variety of symptoms that can vary widely from person to person, and even from attack to ...

More than a billion people worldwide struggle to find relief from the unbearable pain of migraine. But research is leading to new therapies against this debilitating condition.

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine. CGRP may ...

Discover how rimegepant (Nurtec ODT) works for both migraine treatment and prevention. Learn about the approved age range, ...

Please provide your email address to receive an email when new articles are posted on . Rimegepant offered superior sustained pain relief, pain freedom and normal function up to 48 hours. Most adverse ...

The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP ...

It starts with flashes of light. Zig-zag lines float across your vision. You feel a slight tingling in your cheeks and limbs. Then comes a stabbing headache so intense you forget everything—what you ...